"Step Pharma Secures €38M in Series C Funding to Advance Targeted Cancer Therapies"

"Alerion law firm has assisted Step Pharma, a global leader in CTPS1 inhibition for targeted cancer treatment, in raising €38 million in a Series C funding round. The investment was led by V-Bio Ventures, with participation from existing investors including Pontifax and Bpifrance. Founded in 2014, Step Pharma aims to revolutionize cancer treatment with targeted therapies that destroy cancer cells while preserving healthy ones. The funding will accelerate the development of dencatistat, an oral CTPS1 inhibitor, and support the company's strategy to advance it to phase 2 trials for various cancer indications."

The law firm Alerion assisted Step Pharma, a global leader in CTPS1 inhibition for targeted cancer treatment, in its Series C fundraising round amounting to €38 million. This transaction was led by the new investor V-Bio Ventures, based in Ghent, Belgium, with participation from historical investors including Pontifax, Bpifrance, Kurma Partners, Hadean Ventures, Sunstone Life Science Ventures, and Inserm Transfert Initiative. The fundraising will accelerate the development of dencatistat, an oral CTPS1 inhibitor currently in development for the treatment of cancers and hematological diseases. This financing also supports the company's "pipeline in a product" strategy, which aims to advance dencatistat to Phase 2 and confirm its efficacy in several indications. The Alerion team involved in this transaction included Pierre-Olivier Brouard (partner), Benoit Deramoudt (counsel), and Tom Ha (associate).

"Step Pharma Secures €38M in Series C Funding to Advance Targeted Cancer Therapies"

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads